On March 8, 2022 Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results of its proprietary, non-viral gene monoclonal antibody (GMAB) platform technology has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, taking place April 8 – 13, 2022 in New Orleans, LA (Press release, Gennao Bio, MAR 8, 2022, View Source [SID1234609705]). Gennao’s GMAB platform utilizes a novel, cell-penetrating antibody to non-covalently form complexes with and systemically target and deliver effective levels of nucleic acids, including immune-stimulating synthetic RNA, to solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the oral presentation are as follows:

Title: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody
Abstract Control Number: 6710
Session Title: Immune Checkpoint and Immune Modulatory Therapy
Session Type: Minisymposium
Session Date and Time: Sunday, April 10, 2022; 3:00 p.m. – 5:00 p.m. Central Daylight Time
Presenter: Elias Quijano, Yale School of Medicine